The Montpellier-based company MB Therapeutics has closed a financing round of two million euros. The round was led by Beprep, Calyseed, Angels Santé, Banque Publique d’Investissement (BPI) and business angels, including pharmaceutical experts such as Sébastien Gallice. MB Therapeutics develops technologies for the additive manufacturing of customized drugs and thus focuses on an innovative approach in personalized medicine.
The production of medicines using 3D printing enables the dosage to be precisely adapted to the specific needs of patients. This offers advantages in the treatment of diseases such as high blood pressure or in the development of child-friendly dosage forms. The technology differs from conventional manufacturing processes as it enables customized solutions while improving the quality and reproducibility of the preparations.
In Europe, over 1,000 pharmacies and hospital laboratories specialize in the patient-specific production of medicines. Currently, this is mostly done manually, which poses challenges in terms of quality standards, production capacity and availability. MB Therapeutics provides these facilities with modern 3D printers and pre-configured cartridges with standardized pharmaceutical formulations. This enables the production of orodispersible tablets directly on site. The integration of this technology not only increases efficiency, but also improves staff safety and ensures seamless traceability.
In addition to the individualization of medicines, MB Therapeutics’ technology helps to reduce supply bottlenecks and pharmaceutical waste. The French medicines authority ANSM reports that the number of reported supply shortages has increased tenfold in the last ten years. The possibility of producing medicines directly in pharmacies or hospitals reduces dependencies on centralized supply chains and at the same time reduces material consumption.
MB Therapeutics is revolutionizing drug production and addressing contemporary challenges by reducing logistical dependencies and minimizing waste: “Local production in community or hospital pharmacies of tailor-made medicines ensures rapid availability and precise dosages, essential for urgent and personalized care,” explained Dr. Stéphane Roulon, CEO and Co-founder of MB Therapeutics.
The company plans to use the secured financing to bring three highly sought-after drugs to market and prepare for a further financing round in 2026. The development of new dosage forms and the broad availability of personalized medicines are the focus of further expansion.
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
